Liquid Biopsy Market Size Worth USD 13.81 Billion by 2030 at 20.20% CAGR – Report by Market Research Future (MRFR)

According to a Comprehensive Research Report by Market Research Future (MRFR), “Liquid Biopsy Market Information by Biomarker Types, Application, Sample and Region – Forecast till 2030“, the market size was valued at USD 3.17 billion in 2021 and is projected to grow from USD 3.81 Billion in 2022 to USD 13.81 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 20.20% during the forecast period (2022 – 2030).

Market Dynamics

Surging demand for advanced diagnosing equipment coupled with the rising number of research laboratories in the developing economies are the key market drivers enhancing the market growth. The federal government’s increased support will likely accelerate market expansion. Public and private actors, particularly in developing nations, will drive the growth and expansion of the healthcare sector, opening up attractive market expansion potential. Additionally, the market will benefit from the high return on investment that research efforts are guaranteed to produce. The introduction of technologically advanced products in hospitals, increased investment in the development of cutting-edge medical products and devices and rising demand for minimally invasive surgery have all contributed to a positive increase in the liquid biopsy market CAGR globally in recent years. This is especially true of government initiatives to raise awareness, particularly in developing economies.

Get Free Sample PDF Brochure @ https://www.marketresearchfuture.com/sample_request/710

Report Scope:

Report AttributeDetails
Market Size in 2030USD 13.81 Billion
CAGR20.20%
Base Year2022
Forecast Period2023-2030
Historical Data2021
Forecast UnitsValue (USD Billion)
Report CoverageRevenue Forecast, Competitive Landscape, Growth Factors, and Trends
Segments CoveredBy Biomarker Types, Application, Sample
Geographies CoveredNorth America, Europe, Asia-Pacific, and Rest of the World (RoW)
Key Market DriversGovernment investments on healthcare infrastructure to boost market growth
Increased awareness about the cancer is boosting the liquid biopsy market growth

Additionally, over the past ten years, governments from different nations and health organizations have launched a number of campaigns to raise awareness about cancer. For instance, the National Cancer Control Program of the WHO is a public health initiative with the goal of lowering the death toll from cancer and enhancing the quality of life for cancer patients. Similar to this, the US Centers for Diseases and Prevention (CDC) launched the National Breast and Cervical Cancer Early Detection Program (NBCCEDP) in 1991, which annually offers breast cancer screening and diagnosis to low-income and uninsured patients in the US. This programme offered 260,143 women breast cancer diagnostic and screening services in 2020. In the same year, 116,562 women received diagnostic and screening services for cervical cancer through this programme.

Additionally, as a result of liquid biopsy technology’s ability to diagnose cancer early, track tumor growth, and determine clinical prognosis, the market for liquid biopsies is expanding. Additionally, the spread of modern technologies has increased the need for non-invasive diagnosis and therapies, which is anticipated to fuel the demand for liquid biopsies in the years to come. The market participants’ increasing spending in clinical trials for the creation of novel diagnostic approaches are significantly boosting the market revenue for liquid biopsy.

However, increased investment in research and development, particularly in developed and developing nations, will further open up attractive market expansion potential for medical instruments and devices. The market growth rate is also being boosted by pharmaceutical and biopharmaceutical countries’ research and development capabilities for the incorporation of cutting-edge technology in healthcare facilities.

Browse In-depth Market Research Report (171 Pages) on Liquid Biopsy: https://www.marketresearchfuture.com/reports/liquid-biopsy-market-710

Liquid Biopsy Market Competitive Analysis

Major industry companies are investing a lot of money in R&D to expand their product portfolios, which will spur further growth in the liquid biopsy market. With significant industry changes like new product releases, contractual agreements, mergers and acquisitions, increased investments, and collaboration with other organizations, market participants are also undertaking a variety of strategic activities to expand their global presence. In order to grow and remain in a market that is becoming more and more competitive, liquid biopsy competitors must provide affordable products.

Manufacturing locally to cut operational costs is one of the main business tactics used by manufacturers in the liquid biopsy sector to benefit customers and increase the market sector. Major players in the liquid biopsy industry, including F. Hoffmann-La Roche Ltd. (Switzerland), Myriad Genetics, Inc. (US), QIAGEN (Netherlands), and others, are attempting to increase market demand by funding R&D initiatives.

    Written by

    Market Research Future

    Market Research Future (MRFR) is a global market research company that takes pride in its services, offering a complete and accurate analysis regarding diverse markets and consumers worldwide. Market Research Future has the distinguished objective of providing the optimal quality research and granular research to clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help answer your most important questions.

    Leave a Comment